Plain-English translation of NCT07160400 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called IBI3032 designed to help with weight management. Researchers want to understand how safe the medication is, how well people tolerate it, and how the body processes it. The study includes two parts: one group of healthy volunteers will receive a single dose, and another group of people with overweight or obesity will receive multiple doses over four weeks.
Currently, there are limited treatment options for people struggling with weight management. This medication is being studied to see if it could be a safe and effective new choice for those who need help with their weight.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will either receive a single dose of the medication (Part A) or multiple doses over four weeks (Part B), depending on which group you are in. You will have regular visits where researchers will check your blood work, take your vital signs, and monitor how you feel. The medication will be taken by mouth, and you will also receive a placebo (inactive pill) in some visits so researchers can compare the results fairly.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
China